Skyhawk Therapeutics, Inc. is a Massachusetts-based biotechnology company. Its recent lobbying work, reported in filings, focused on federal tax rules about whether research and development (R&D) expenses are deductible. The company hired FGS Global to represent its interests on this R&D tax deductibility issue.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
PAUL POTEET
The latest disclosures for this client.
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
Q1FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
RACHEL ALEXANDER
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
RA